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Introduction: Hypoxia-inducible factor-1 (HIF-1), which plays
an essential role in the adaptive response of cells to hypoxia, is
associated with aggressive tumor behavior. Furthermore, a rela-
tionship between excision repair cross-complementing 1
(ERCC1) expression and platinum resistance has been reported in
patients with various malignancies. The aim of this study was to
investigate the expression of HIF-1 and ERCC1 and to elucidate
the clinical significance of their expression in patients with small
cell lung cancer (SCLC) treated with front-line platinum-based
chemotherapy.
Methods: SCLC biopsy samples were obtained before front-line
platinum-based chemotherapy from 111 patients with SCLC (lim-
ited disease, 29; extensive disease [ED], 82) between January 2002
and December 2009 at Gyeongsang National University Hospital.
The expression levels of HIF-1 and ERCC1 were assessed by
immunohistochemistry.
Results: High expression levels of ERCC1 and HIF-1 were ob-
served in 49 (44.1%) and 71 (64.0%) of 111 patients, respectively.
Expression of ERCC1 and HIF-1 was not significantly associated
with age, sex, Eastern Cooperative Oncology Group performance
status, weight loss, or response to treatment, regardless of stage. In
ED-SCLC, low expression in the HIF-1 group showed statistically
better survival compared with high expression in the HIF-1 group
(p  0.018). Multivariate analysis revealed that response to front-
line platinum-based chemotherapy (p  0.001), good Eastern Co-
operative Oncology Group performance status (0–1) (p  0.002),
and low expression of HIF-1 (p  0.004) were independent
predictors of better overall survival in ED-SCLC.
Conclusions: Low expression of HIF-1 may be a useful predictor
of better overall survival in ED-SCLC patients treated with front-
line platinum-based chemotherapy.
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Small cell lung cancer (SCLC) represents approximately15% of all new cases of lung cancer in the United States,
Europe, and Korea,1–7 with highly aggressive clinical behav-
ior involving rapid growth and early extrathoracic metasta-
ses.1–7 Platinum-based combination chemotherapy is cur-
rently considered to be the mainstay of standard treatment for
both limited disease (LD) and extensive disease (ED)
SCLC,1–7 but despite its initial high response to platinum-
based chemotherapy, the emergence of drug resistance and
lack of effective salvage therapies result in poor prognoses in
patients with SCLC.1–7 Therefore, a better understanding of
SCLC biology could enable us to predict response, recur-
rence, and survival and may lead to novel and effective
therapeutic breakthroughs in relapsed or refractory SCLC
after front-line platinum-based chemotherapy.
The DNA repair mechanism is a crucial molecular
pathway potentially involved in resistance to platinum-based
chemotherapy.8–17 Enzyme excision repair cross-comple-
menting 1 (ERCC1) plays a leading role in the nucleotide
excision repair pathway, and a relationship between ERCC1
expression and platinum resistance has been reported in
patients with gastric, bladder, ovarian, colorectal, esophageal,
non-SCLC, and SCLC8–17; hypoxia-inducible factor-1
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(HIF-1) is the key regulator of the cellular response to
hypoxia, which could induce the transcription of many genes
involved in metabolic adaptation, apoptosis resistance, neo-
angiogenesis, tumor invasion, and metastasis.18–26 Moreover,
recent studies have demonstrated that overexpression of
HIF-1 is associated with poorer clinical outcomes in pa-
tients with various malignancies.18–26
In this study, we evaluated the clinical significance of
ERCC1 and HIF-1 expression as a predictive marker for
both response to treatment and survival in patients with
SCLC treated with front-line platinum-based chemotherapy.
PATIENTS AND METHODS
Patient Characteristics and Samples
In this retrospective study, SCLC samples were ob-
tained from 111 patients treated with platinum-based chemo-
therapy as a front-line regimen for both LD-SCLC and
ED-SCLC between January 2002 and December 2009 at
Gyeongsang National University Hospital after receiving
written informed consent from all subjects. The pathologi-
cally proven SCLC patients were treated with platinum (cis-
platin 60–70 mg/m2 or carboplatin area under the curve 4–5)
plus either etoposide (100 mg/m2 on days 1–3) or irinotecan
(60–65 mg/m2 on days 1 and 8). The treatment cycles were
repeated every 3 weeks. Concurrent thoracic radiotherapy
was allowed for patients who had LD-SCLC with good
performance status, and prophylactic cranial irradiation was
allowed irrespective of the stage of SCLC. The Veterans
Administration Lung Study Group system was used for stag-
ing of the patients.
The response to platinum-based chemotherapy was
evaluated after completion of two to three courses. This study
was approved by the institutional review board of Gyeong-
sang National University Hospital.
Immunohistochemistry
Immunohistochemical staining of formalin-fixed, par-
affin-embedded tumor tissue obtained before treatment was
performed using anti-ERCC1 mouse monoclonal antibody
(8F1 diluted 1:100; Abcam, Cambridge, MA) and anti-HIF
alpha mouse monoclonal antibody (H1alpha67 1:100; Ab-
cam). In brief, for epitope retrieval, specimens for anti-
ERCC1 antibody were exposed to 10 mM citrate buffer (pH
6.0) and heated for 30 minutes in a water bath. Specimens for
anti-HIF-1 antibody were performed by microwave antigen
retrieval in citrate buffer. Tumor sections were incubated for
60 minutes with primary antibodies. Antibody binding was
detected by an UltraVision Detection System Anti-Mouse,
horseradish peroxidase/diaminobenzidine (Thermo Scientific,
Fremont, CA) and Mayer’s hematoxylin as the counter-
stain.6–15,21 Sections of normal tonsil tissues were included as
external positive controls, and stromal cells surrounding the
tumor area served as internal positive controls.6–15
Immunohistochemical Assessment
Expression of ERCC1 was quantified using a visual
grading system based on the extent of staining (percentage of
positive tumor cells) (graded on a scale of 0–3; 0  none,
1  1–9%, 2  10–49%, 3  50%) and the intensity of
staining (graded on a scale of 0–3; 0  negative, 1  weak
staining, 2  moderate staining, 3  positive). The expres-
sion of these proteins was considered as high expression of
ERCC1 when tumors had a staining intensity score of 2 and
50% positive nuclei or a staining intensity score of 3 and
10% positive nuclei.6–15
The expression of HIF-1 was considered to be high
when nuclear staining occurred in 10% of the tumor cells;
concomitant cytoplasm staining was not6–15 counted because
HIF-1 protein in the nucleus determined the functional
activity of the HIF-1 complex.21–23
Statistical Analysis
The clinical data were analyzed according to informa-
tion available as of February 2011. The clinical characteris-
tics and treatment outcomes of the patients were compared
according to expression of ERCC1 and HIF-1 using 2 test,
Fisher’s exact test, or Mann-Whitney U test.
Survival probability analyses were performed using the
Kaplan-Meier method. Overall survival (OS) was calculated
from the date that chemotherapy began to the date of death or
most recent follow-up.
In this study, progression-free survival is defined as the
date that chemotherapy began to the date of first documen-
tation of radiologic progression or death due to any cause.
Significance between group differences was assessed
by the log-rank test. Multivariate analyses were performed
using Cox regression models for OS. Factors with p values
0.1 in univariate analyses were examined with multivariate
regression models. All statistical tests were two-sided, with
significance defined as p  0.05. Analyses were performed
using SPSS version 12.0 (SPSS Inc., Chicago, IL).
RESULTS
Characteristics of Patients
The 111 patients (93 men and 18 women) had a median
age of 65 years (range, 44–80 years). Patient baseline demo-
graphic and clinical characteristics are listed in Table 1.
Thirty-three patients (29.7%) had an Eastern Cooperative
Oncology Group (ECOG) performance status of 2 to 3.
Among the 82 patients with ED-SCLC, 39 were treated with
etoposide and platinum (EP) and 43 with irinotecan and
platinum (IP). All LD patients with SCLC received only EP
as a front-line chemotherapy. Eighty-three patients (74.8%)
showed complete response or partial response after platinum-
based chemotherapy.
Association of Biological Marker Expression
with Clinical Characteristics According to
Stage
Among the 111 patients, high expression of ERCC1
and HIF-1 was observed in 49 (44.1%) and 71 (64.0%),
respectively (Figure 1). Expression of ERCC1 and HIF-1
was not significantly associated with age, sex, ECOG perfor-
mance status, weight loss, or response to treatment, regard-
less of stage (Tables 2 and 3).
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Survival According to Chemotherapeutic
Agents
Four patients in LD-SCLC and nine in ED-SCLC were
treated with carboplatin-based chemotherapy among the 111
patients. There was no significant difference of OS between
carboplatin arm and cisplatin arm in this study, regardless of
stage (p  0.224 in LD-SCLC; p  0.330 in ED-SCLC).
In ED-SCLC, no significant difference of OS was
observed between EP and IP (EP: median OS, 7.16 months
[range, 5.38–8.94 months] versus IP: median OS, 9.53
months [range, 7.67–11.40 months]) (p  0.087).
Survival and Expression of ERCC1 and HIF-1
At a median follow-up of 32.1 months (range, 5.5–88.4
months), median OS was 18.1 months in the LD-SCLC group
and 9.0 months in the ED-SCLC group (p  0.001).
In LD-SCLC, the median OS was 20.54 months (range,
13.70–26.29 months) in the low expression of ERCC1 and
12.87 months (range, 3.83–22.86 months) in the high expres-
sion of ERCC1 (p  0.106) (Figure 2A). No significant
survival difference was observed between low expression of
HIF-1 (median OS, 20.00 months [range, 11.72–28.27
months]) and high expression of HIF-1 (median OS, 14.55
months [range, 10.07–19.04 months]) in LD (p  0.502)
(Figure 2C).
In ED-SCLC, no significant difference of OS was
observed between low expression of ERCC1 and high
ERCC1 (low ERCC1: median OS, 9.08 months [range, 7.56–
10.57 months] versus high ERCC1: median OS, 8.98 months
[range, 7.19–10.76 months]) (p  0.322) (Figure 2B). How-
ever, the group with low expression of HIF-1 (median OS,
13.63 months [range, 8.54–18.72 months]) showed statisti-
cally better survival compared with the group with high
expression of HIF-1 (median OS, 7.86 months [range,
7.79–10.16 months]) (p  0.018) (Figure 2D).
FIGURE 1. Immunohistochemical staining of
excision repair cross-complementing 1 (ERCC1)
and hypoxia-inducible factor-1 (HIF-1) in
small cell lung cancer (400). (A) High expres-
sion of ERCC1. (B) Low expression of ERCC1.
(C) High expression of HIF-1. (D) Low expres-
sion of HIF-1.
TABLE 1. Characteristics of Patients
Characteristics Number (%)
Median age, yr (range) 65 (44–80)
Sex
Male 93 (83.8)
Female 18 (16.2)
ECOG PS
0–1 78 (70.3)
2 28 (25.2)
3 5 (4.5)
Stage
Limited disease 29 (26.1)
Extensive disease 82 (73.9)
Site of metastases (only ED  82)
Adrenal gland 16 (19.5)
Liver 39 (47.6)
Bone 35 (42.7)
Central nervous system 11 (13.6)
Others 32 (39.0)
Front-line chemotherapy
Etoposide/platinum 68 (61.3 LD, 29; ED, 39)
Irinotecan/platinum 43 (38.7)
Platinum-based chemotherapy
Carboplatin arm 13 (11.7 LD, 4; ED, 9)
Cisplatin arm 98 (88.3 LD, 25; ED, 73)
Prophylactic cranial irradiation
Yes 44 (39.6 LD, 21; ED, 23)
No 67 (60.4 LD, 8; ED, 59)
Chemotherapy response
Responder (CR  PR) 83 (74.8)
Nonresponder (SD  PD) 23 (20.7)
Not evaluable 5 (6.1)
ECOG PS, Eastern Cooperative Oncology Group performance status; LD, limited
disease; ED, extensive disease; CR, complete response; PR, partial response; SD, stable
disease; PD, progressive disease.
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No significant difference of progression-free survival
was found according to expression of ERCC1 or HIF-1
irrespective of stage (Table 4).
Univariate analysis showed that better OS was signifi-
cantly associated with response to front-line platinum-based
chemotherapy (p  0.001), good ECOG performance status
(0–1) (p 0.001), and low expression of HIF-1 (p 0.002)
in ED-SCLC and good ECOG performance status (0–1) (p
0.004) in LD-SCLC.
Multivariate analysis revealed that response to front-
line platinum-based chemotherapy (p  0.001), good
ECOG performance status (0–1) (p  0.002), and low
expression of HIF-1 (p  0.004) were independent pre-
dictors of better OS in ED-SCLC. However, in patients
with LD-SCLC, good ECOG performance status (0–1)
alone was an independent prognostic factor of better OS
(p  0.031) (Table 5).
DISCUSSION
Recent studies revealed that hypoxia can regulate
vascular endothelial growth factor (VEGF) expression by
elevating the HIF-1 translation rate and stability via
activation of mitogen-activated protein kinase or the phos-
phatidylinositol 3-kinase-Akt pathway,24,27–29 while an-
other study showed that each step of the metastasis process
can potentially be regulated by hypoxia, suggesting a key
regulator role of hypoxia and HIFs in metastasis.18 Al-
though SCLC is a heterogeneous tumor in which tumor
growth is dependent on the dysregulation of multiple
signaling pathways, HIF-1 and HIF-1-dependent
TABLE 2. Clinical Characteristics and Expression of ERCC1
According to Stage
Characteristics
ERCC1 Expression
pHigh (n  10) Low (n  19)
Limited disease
Age (yr) 0.518
65 4 10
65 6 9
Sex 0.197
Male 9 13
Female 1 6
ECOG PS 0.482
0–1 8 17
2–3 2 2
Weight loss (5%) 0.523
Yes 3 8
No 7 11
Response to treatment 0.460
Responder (CR  PR) 10 18
Nonresponder (SD  PD) 0 1
High (n  39) Low (n  43)
Extensive disease
Age (yr) 0.358
65 16 22
65 23 21
Sex 0.880
Male 34 37
Female 5 6
ECOG PS 0.382
0–1 18 24
2–3 21 19
Weight loss (5%) 0.395
Yes 19 23
No 20 20
Response to treatment 0.437
Responder (CR  PR) 25 31
Nonresponder (SD  PD) 14 12
ECOG PS, Eastern Cooperative Oncology Group performance status; ERCC1,
excision repair cross-complementing 1; CR, complete response; PR, partial response;
SD, stable disease; PD, progressive disease.
TABLE 3. Clinical Characteristics and Expression of HIF-1
According to Stage
Characteristics
HIF-1 Expression
pHigh (n  11) Low (n  18)
Limited disease
Age (yr) 0.196
65 7 7
65 4 11
Sex 0.229
Male 7 15
Female 4 3
ECOG PS 0.592
0–1 9 16
2–3 2 2
Weight loss (5%) 0.514
Yes 5 6
No 6 12
Response to treatment 0.193
Responder (CR  PR) 10 18
Nonresponder (SD  PD) 1 0
High (n  60) Low (n  22)
Extensive disease
Age (yr) 0.550
65 29 9
65 31 13
Sex 0.134
Male 54 17
Female 6 5
ECOG PS 0.388
0–1 29 13
2–3 31 9
Weight loss (5%) 0.971
Yes 33 12
No 27 10
Response to treatment 0.290
Responder (CR  PR) 39 17
Nonresponder (SD  PD) 21 5
ECOG PS, Eastern Cooperative Oncology Group performance status; HIF-1,
hypoxia-inducible factor-1; CR, complete response; PR, partial response; SD, stable
disease; PD, progressive disease.
Journal of Thoracic Oncology • Volume 7, Number 3, March 2012 HIF-1 in SCLC
Copyright © 2012 by the International Association for the Study of Lung Cancer 531
VEGFs might be implicated in tumor initiation, growth,
invasion, and metastases among the important biomarkers
in SCLC.18,24,27–30
The evidence that HIF-1 and HIF-1-dependent
VEGFs play pivotal roles in SCLC is as follows. First, HIF-1
 is overexpressed in 43 to 46% of patients with SCLC, and
FIGURE 2. Overall survival of patients with small cell lung cancer according to the expression of excision repair cross-comple-
menting 1 (ERCC1) and hypoxia-inducible factor-1 (HIF-1). A, OS between low ERCC1 and high ERCC1 in LD; B, OS between low
HIF-1 and high HIF-1 in LD; C, OS between low ERCC1 and high ERCC1 in ED; D, OS between low HIF-1 and high HIF-1 in ED.
TABLE 4. Progression-Free Survival (PFS) of Patients with Small Cell Lung Cancer
According to the Expression of ERCC1 and HIF-1
High ERCC1 (n  10) Low ERCC1 (n  19) p
PFS in LD 7.19 mo (3.01–14.63 mo) 9.87 mo (6.58–17.41 mo) 0.252
High ERCC1 (n  39) Low ERCC1 (n  43)
PFS in ED 4.42 mo (3.41–6.14 mo) 5.49 mo (3.87–5.78 mo) 0.407
High HIF-1 (n  11) Low HIF-1 (n  18)
PFS in LD 7.31 mo (4.26–12.07 mo) 9.24 mo (5.82–18.36 mo) 0.316
High HIF-1 (n  60) Low HIF-1 (n  22)
PFS in ED 4.87 mo (4.17–6.58 mo) 6.73 mo (4.95–9.24 mo) 0.341
ERCC1, excision repair cross-complementing 1; HIF-1, hypoxia-inducible factor-1; PFS, progression-free survival;
LD, limited disease; ED, extensive disease.
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overexpression of HIF-1 has been considered to be a sig-
nificant prognostic factor related to poorer OS in SCLC as
well as non-SCLC.20,21 Second, topoisomerase I inhibitor, a
topotecan that can inhibit HIF-1 protein translation with
antitumor effects, has been accepted as an effective standard
salvage treatment for ED-SCLC.18,31–35 Third, an Italian
study demonstrated that a high vascular count and overex-
pression of VEGF, which might be related to HIF-1, are
associated with an unfavorable prognosis in operated
SCLC.30 Fourth, some experimental studies on inhibition of
the HIF-1 pathway and HIF-1 transcriptional activity,
including VEGF monoclonal antibody and multitargeted
VEGF tyrosine kinase inhibitors, in xenograft models of
SCLC also reported promising antitumor activities.18,31–35
Fifth, therapeutic agents targeting mammalian target of rapa-
mycin, ERBB2, and mitogen-activated protein/extracellular
signal-regulated kinase also decreased the HIF-1 level,
which may partially account for their antitumor activities
because HIF-1 can be induced by hypoxia-independent
signaling pathways.18 To our knowledge, this is the first study
to demonstrate the clinical significance of HIF-1 as a more
important prognostic factor in patients with SCLC compared
with ERCC1 on both univariate and multivariate analyses.
Although Greek studies showed a significant correla-
tion between HIF-1 and VEGF using immunohistochemis-
try in SCLC biopsy specimens,21 no clinical association was
shown between their expression level and clinical outcomes
such as stage, performance status, treatment response, and
survival. ERCC1, however, is still considered to be an im-
portant prognostic factor in various malignancies as well as
SCLC.6,8–17
Although previous studies using immunohistochem-
istry, quantitative real-time polymerase chain reaction, and
genetic analysis of single nucleotide polymorphism
showed a clinical significance of ERCC1,6,8–17 the data on
the predictive value of ERCC1 in SCLC patients treated
with front-line platinum-based chemotherapy were also
retrospectively analyzed, and limited studies demonstrated
ERCC1 as a predictive marker of OS only in LD.6
Similar to previous studies that investigated ERCC1,6
our study showed that high expression of ERCC1 was found
in 49 patients (44.1%). Although the Kaplan-Meier survival
curve seemed to show better survival tendency in patients
with low expression of ERCC1 regardless of stage in our
study, this difference was not statistically significant.
A few previous studies pointed out ERCC1 as a pre-
dictive marker in LD SCLC patients related with long-term
remissions and survival.36 The discrepancy between previous
studies and our results in the ERCC1 analysis might be
explained by the relatively small number of LD-SCLC in our
study. However, further prospective study should be needed
to justify the predictive value of ERCC1 in SCLC because
these previous studies were also retrospectively analyzed.
Despite clinical trials that attempted to find better
treatments and outcomes with new agents alone, such as
sorafenib, bevacizumab, proteasome inhibitor, and mamma-
lian target of rapamycin inhibitor or combinations with stan-
dard cytotoxic agents,31–35 platinum-based chemotherapy still
remains the standard front-line treatment for SCLC irrespec-
tive of stage.18,31–36 Therefore, further investigations in
searching for pivotal biomarkers and emergence mechanisms
of drug resistance in SCLC are necessary because many
hidden mechanisms of SCLC carcinogenesis and drug resis-
tance remain which have not been fully evaluated. Moreover,
further clinical trials should be performed to determine the
most appropriate treatment targeting hypoxia and the HIF-1.
In conclusion, low expression of HIF-1 may be a
useful predictor of better OS in ED-SCLC patients treated
with front-line platinum-based chemotherapy, although fur-
ther large prospective studies are needed to validate our
findings.
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